3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Small Cell Lung Carcinoma
3
Sarcoma
3
Carcinoma, Transitional Cell
3
Stomach Neoplasms
2
Pancreatic Neoplasms
2
Mesothelioma, Malignant
2
Melanoma
2
Lung Neoplasms
2
Carcinoma, Renal Cell
2
Brain Neoplasms
2
Uterine Cervical Neoplasms
1
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Thymoma
1
Tertiary Lymphoid Structures
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Glioblastoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Nivolumab
4
pembrolizumab
2
durvalumab
2
regorafenib
1
fludarabine phosphate
1
fludarabine
1
danvatirsen
1
avelumab
1
atezolizumab
1
Ipilimumab
1
Interleukin-2
1
Immunoglobulin G
1
Docetaxel
1
Disulfides
1
Cyclophosphamide
1
Clinical Trials, Phase II as Topic
1
ALT-803
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Turcot syndrome
×
regorafenib
×
Thoracic
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled